Induction of tumor-specific CTL after mini-transplantation for advanced pancreatic cancer

Induction of tumor-specific CTL after mini-transplantation for advanced pancreatic cancer - Allogeneic immunotherapy against pancreatic cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000349

Enrollment

Registered

2006-03-10

Start date

2004-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Peptide vaccination after mini-transplantation.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pancreatic cancer not amenable to curative resection. Patients must have an HLA-matched or one-locus-mismatched related donor. HLA-A2402 positive. Serum CEA above upper normal limit.

Exclusion criteria

Exclusion criteria: ECOG PS 2-4

Design outcomes

Primary

Measure	Time frame
Adverse events associated with peptide vaccination	—

Secondary

Measure	Time frame
Induction of CTL Tumor response	—

Countries

Japan

Contacts

Public ContactYoshinobu Kanda

University of Tokyo Hospital Department of Hematology & Oncology

ycanda-tky@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026